Method for determining, predicting and treating cancer
AssigneeKaohsiung Medical University
InventorYi-Ming Chen
Life of this patent
Estimating the term…
Abstract
Disclosed herein are methods of detecting or making a risk evaluation of a cancer that has a mutated PREX2 expressed thereon. The cancer may be a primary cancer, a metastatic cancer or a recurrent cancer. According to the embodiment of the present disclosure, the mutation is G258V, S1113R, E1346D or K400fs. Also disclosed herein are methods of treating the subject in need thereof.
Claims21
1-13. (canceled)
A method of making a prognosis of the metastasis or recurrence of a cancer in a subject, comprising:
- obtaining a biological sample from the subject;
- extracting a DNA from the biological sample;
- and
- detecting a presence or absence of a mutation in a phosphatidylinositol 3,4,5-trisphosphate Rac exchange factor 2 (PREX2) gene, wherein:
- the mutation is one selected from the group consisting of G773T, A3337C, A4038T, 1200 delG and the combination thereof;
- and
- the presence of the mutation indicates the subject has a risk of developing metastatic or recurrent cancers.
A method of treating a subject having or suspected of having a cancer that has a phosphatidylinositol 3,4,5-trisphosphate Rac exchange factor 2 (PREX2) expressed thereon, comprising:
- administering to the subject an effective amount of a composition,
- wherein the PREX2 comprises at least one mutation being one selected from the group consisting of G258V, S1113R, E1346D and K400fs, and the composition comprises a therapeutic molecule and a targeting molecule conjugated with the therapeutic molecule, wherein the targeting molecule exhibits a binding affinity to the PREX2.
A method of determining whether a subject has or is at risk of developing a cancer, comprising:
- obtaining a biological sample from the subject;
- extracting a DNA from the biological sample;
- and
- detecting a presence or absence of a mutation in a phosphatidylinositol 3,4,5-trisphosphate Rac exchange factor 2 (PREX2) gene in the DNA;
- and
- determining that the subject has or is at risk of developing the cancer when the mutation is present.
Dependencies are inferred from the claim text.